ArticleTransplant infectious disease : an official journal of the Transplantation Society2017
Epidemiology of infections following haploidentical peripheral blood hematopoietic cell transplantation.
Article in Transplant infectious disease : an official journal of the Transplantation Society, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 1 synthesis or guideline pooled it, 92 citations in OpenAlex.
- Systematic overview of HLA-matched allogeneic hematopoietic cell transplantation with post-transplantation cyclophosphamide.International journal of hematology · 2022Pooled it
- Final outcomes from a phase 2 trial of posoleucel in allogeneic hematopoietic cell transplant recipients.Blood advances · 2024Trial
- Myeloablative haploidentical BMT with posttransplant cyclophosphamide for hematologic malignancies in children and adults.Blood advances · 2020Trial
- Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy followed by haploidentical HSCT for relapsed/refractory acute lymphoblastic leukemia: a multi-center retrospective study.Journal of hematology & oncology · 2020Trial
- The Impact of Cytomegalovirus Reactivation on Cytomegalovirus-Specific Immune Reconstitution in Hematopoietic Stem Cell Transplant Recipients Receiving Letermovir Prophylaxis.Open forum infectious diseases · 2026Article
- Comparison of quantitative PCR values and antigenemia for CMV monitoring in hematopoietic cell transplant recipients.International journal of hematology · 2026Article
- Outcomes of allogeneic hematopoietic cell transplantation in patients with carbapenem-resistant organisms infection: a propensity score-matched analysis.Frontiers in transplantation · 2026Article
- Article
- Incidence and Clinical Outcomes of Multiple Viral Infections After Allogeneic Hematopoietic Cell Transplantation.Open forum infectious diseases · 2025Article
- Review
- Exploring facilitators and barriers to daily chlorhexidine gluconate bathing in adult patients undergoing hematopoietic stem cell transplantation.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024Article
- Preneutropenic Fever in Patients With Hematological Malignancies: A Novel Target for Antimicrobial Stewardship.Open forum infectious diseases · 2024Article
- Improving Outcomes with Haploidentical Stem Cell Transplantation [HaploSCT] in Children Using Post-transplant Cyclophosphamide: a Single Center Experience.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2024Article
- Comparison of Infectious Complications in Patients Receiving High-Dose Cyclophosphamide as GvHD Prophylaxis After Transplantation From A 9/10 HLA-Matched Unrelated Donor with Standard GvHD Prophylaxis After Transplant From A Fully Matched Related Donor.Mediterranean journal of hematology and infectious diseases · 2024Article
- Post-transplantation cyclophosphamide is associated with increased bacterial infections.Bone marrow transplantation · 2024Article
- Haploidentical transplant with posttransplant cyclophosphamide vs matched related and unrelated donor transplant in acute myeloid leukemia and myelodysplastic neoplasm.Bone marrow transplantation · 2023Article
- Article
- Invasive Yeast Infection after Haploidentical Donor Hematopoietic Cell Transplantation Associated with Cytokine Release Syndrome.Transplantation and cellular therapy · 2022Article
- Risk prediction of CMV reactivation after allogeneic stem cell transplantation using five non-HLA immunogenetic polymorphisms.Annals of hematology · 2022Article
- Home-Based Hematopoietic Cell Transplantation in the United States.Transplantation and cellular therapy · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
backgroundThe use of T-cell replete haploidentical hematopoietic cell transplant (haplo-HCT) has increased substantially since the introduction of post-transplant cyclophosphamide (PTCy) regimens. Limited data exist concerning infectious complications of haplo-HCT utilizing mobilized peripheral blood (PB) hematopoietic cells.
methodsThis retrospective cohort study included all adult patients at our institution undergoing PB haplo-HCT with PTCy between June 2009 and June 2015. Infections were microbiologically confirmed. Invasive fungal infections (IFI) classified as "proven" or "probable" by standard definitions were included.
resultsIn total, 104 patients were identified. Median follow-up was 218 days (range: 6-1576). A total of 322 episodes of infection were recorded. Eighty-nine percent of patients experienced at least one infection. Median time to first infection was 22 days. Patients experiencing at least one bacterial, viral, and IFI were 62%, 72%, and 6%, respectively. The majority (69%) of bacterial infections were caused by enteric organisms. Seven cases of Staphylococcus aureus infection were recorded, with one bacteremia case. Cytomegalovirus (CMV) viremia occurred in 54/71 (76%) at-risk patients at a median time of 24 days. Sixteen (15%) patients developed CMV disease. Nineteen percent (20/104) of patients developed BK polyomavirus-associated cystitis. Six (6%) patients experienced a total of seven IFI. Infection was the primary cause of death for 12% (6/51) of patients and was a secondary cause for 41%.
conclusionIn PB haplo-HCT patients, a high incidence of CMV viremia and disease was observed. Infections with enteric bacteria were common. Fungal and staphylococcal infections were uncommon. Further studies are needed to compare infectious complications in haplo-HCT with other transplant modalities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.